Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Children's Hospital of Soochow University
- Target Recruit Count
- 500
- Registration Number
- NCT06221683
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳XiangYa Hospital Central South University, Changsha, Hunan, China
🇨🇳Children's Hospital of Soochow University, Suzhou, Jiangsu, China
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Computed TomographyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: DoxorubicinProcedure: EchocardiographyProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateProcedure: Multigated Acquisition ScanBiological: NavitoclaxDrug: PegaspargaseDrug: NelarabineProcedure: Positron Emission TomographyDrug: ThioguanineProcedure: X-Ray ImagingDrug: VenetoclaxDrug: Vincristine
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT06210750
Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
- Conditions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06200220
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06191978
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 41
- Registration Number
- NCT06192979
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 98
- Registration Number
- NCT06191263
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
🇫🇷Centre Hospitalier Le Mans, Le Mans, France
🇫🇷Centre Hospitalier Universitaire De Lille, Lille, France
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT06177067
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Antonio M Jimenez Jimenez
- Target Recruit Count
- 25
- Registration Number
- NCT06158100
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 27
- Registration Number
- NCT06156579
- Locations
- 🇩🇪
University Hospital, Tuebingen, Baden-Wuerttemberg, Germany
CIML NK Cells With Venetoclax for AML
- Conditions
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06152809
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.